Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current HIV Research
  4. Volume 22, Issue 1
  5. Article
Volume 22, Issue 1
  • ISSN: 1570-162X
  • E-ISSN: 1873-4251

Abstract

Background

Early diagnosis and effective antiretroviral therapy (ART) lead to similar life expectancy in people living with HIV (PLWH) compared to the general population. This population faces problems such as decreased bone mineral density (BMD) and increased fracture risk. The aim of this study was to determine the prevalence of osteoporosis in men aged 50 years and over who were PLWH and to determine risk factors and changes in bone metabolism with bone turnover markers.

Methods

79 male PLWH aged 50 years and over were followed up in our outpatient clinic between May 2021 and October 2021. The patients’ demographic, clinical, laboratory, and DEXA data were analyzed. Serum levels of bone turnover markers were measured.

Results

The prevalence of osteopenia, osteoporosis, and normal BMD was found to be 55.7%, 13.9%, and 30.4%, respectively. A correlation was found between low BMD and low body mass index, elapsed time since diagnosis of HIV infection, high rate of use of ART, and long usage time of tenofovir disoproxil fumarate + protease inhibitor. A one-year increase in HIV infection duration was associated with an increased risk of low BMD by 1.246.

Conclusion

Compared to studies conducted on the general population, the prevalence of osteoporosis in male PLWH aged 50 years and older was two times higher. The limited effect of the duration of ART use on low BMD may be due to the patients' histories of replacement therapy. Therefore, to eliminate the negative effects of ART on BMD, it may be beneficial to start replacement therapy when necessary.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X273667231213061301
2024-01-24
2025-01-26

  • From This Site

    /content/journals/chr/10.2174/011570162X273667231213061301
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MallonP.W.G. Aging with HIV.Curr. Opin. HIV AIDS20149442843510.1097/COH.000000000000008024871090
     [Google Scholar]
  2. de AlmeidaL.L. IlhaT.A.S.H. de CarvalhoJ.A.M. SteinC. CaeranG. ComimF.V. MorescoR.N. HaygertC.J.P. CompstonJ.E. PremaorM.O. Sarcopenia and its association with vertebral fractures in people living with HIV.Calcif. Tissue Int.2020107324925610.1007/s00223‑020‑00718‑y32683475
     [Google Scholar]
  3. Tükenmez-TigenE. KortenV. Effects of HIV infection and antiretroviral treatment on the development of osteopenia.Klimik Derg.20122525157
     [Google Scholar]
  4. HoyJ. Bone disease in HIV: Recommendations for screening and management in the older patient.Drugs Aging201532754955810.1007/s40266‑015‑0279‑426123948
     [Google Scholar]
  5. Turkish endocrinology and metabolism association. osteoporosis and metabolic bone diseases diagnosis and treatment guide.Available from: https://temd.org.tr/kilavuzlar
  6. BiverE. Osteoporosis and HIV Infection.Calcif. Tissue Int.2022110562464010.1007/s00223‑022‑00946‑435098324
     [Google Scholar]
  7. PowderlyW.G. Osteoporosis and bone health in HIV.Curr. HIV/AIDS Rep.20129321822210.1007/s11904‑012‑0119‑722581359
     [Google Scholar]
  8. KatzensteinT.L. WessmanM. MoseholmE. SandholdtH. HansenA.B.E. LebechA.M. JørgensenN.R. WeisN. HsuT.C. Prevalence of low bone mineral density among people living with HIV.Cogent Med.202181192066710.1080/2331205X.2021.1920667
     [Google Scholar]
  9. TuzunS. EskiyurtN. AkarirmakU. SaridoganM. SenocakM. JohanssonH. KanisJ.A. Incidence of hip fracture and prevalence of osteoporosis in Turkey: The FRACTURK study.Osteoporos. Int.201223394995510.1007/s00198‑011‑1655‑521594756
     [Google Scholar]
  10. WattanachanyaL. SunthornyothinS. ApornpongT. LwinH.M.S. KerrS. GatechompolS. HanW.M. WichiansanT. SiwamongsathamS. ChattranukulchaiP. ChaiwatanaratT. AvihingsanonA. Bone mineral density among virologically suppressed Asians older than 50 years old living with and without HIV: A cross-sectional study.PLoS One20221711e027723110.1371/journal.pone.027723136409740
     [Google Scholar]
  11. Chiţu-TișuC.E. BarbuE.C. LazărM. IonD.A. BădărăuI.A. Low bone mineral density and associated risk factors in HIV-infected patients.Germs201662505910.11599/germs.2016.108927482514
     [Google Scholar]
  12. LimaA. de OliveiraP.R. PlaplerP.G. MarcolinoF.M. de Souza MeirellesE. SugawaraA. GobbiR.G. Dos SantosA.L. CamanhoG.L. Osteopenia and osteoporosis in people living with HIV: Multiprofessional approach.HIV AIDS2011311712410.2147/HIV.S661722267944
     [Google Scholar]
  13. CarrA. GrundB. NeuhausJ. SchwartzA. BernardinoJ.I. WhiteD. Badel-FaesenS. AvihingsanonA. EnsrudK. HoyJ. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: A substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.HIV Med.201516S113714610.1111/hiv.1224225711332
     [Google Scholar]
  14. DelpinoM.V. QuarleriJ. Influence of HIV infection and antiretroviral therapy on bone homeostasis.Front. Endocrinol.20201150210.3389/fendo.2020.0050232982960
     [Google Scholar]
  15. AydınO.A. KaraosmanogluH.K. KarahasanogluR. TahmazM. NazlıcanO. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients.Braz. J. Infect. Dis.201317670771110.1016/j.bjid.2013.05.00924076108
     [Google Scholar]
  16. DuttaD. GargaU. GadpayleA. BansalR. AnandA. GauravK. SharmaL. SharmaN. Occurrence & predictors of osteoporosis & impact of body composition alterations on bone mineral health in asymptomatic pre-menopausal women with HIV infection.Indian J. Med. Res.2018147548449510.4103/ijmr.IJMR_1196_1630082573
     [Google Scholar]
  17. BonjochA. FiguerasM. EstanyC. Perez-AlvarezN. RosalesJ. del RioL. di GregorioS. PuigJ. GómezG. ClotetB. NegredoE. Osteoporosis Study Group High prevalence of and progression to low bone mineral density in HIV-infected patients: A longitudinal cohort study.AIDS201024182827283310.1097/QAD.0b013e328340a28d21045635
     [Google Scholar]
  18. MoranC.A. Neale WeitzmannM. OfotokunI. Bone loss in HIV infection.Curr. Treat. Options Infect. Dis.201791526710.1007/s40506‑017‑0109‑928413362
     [Google Scholar]
  19. BirabaharanM. KaelberD.C. KarrisM.Y. Bone mineral density screening among people with HIV: A population-based analysis in the United States.Open Forum Infect. Dis.202183ofab08110.1093/ofid/ofab08133796595
     [Google Scholar]
  20. StellbrinkH.J. OrkinC. ArribasJ.R. CompstonJ. GerstoftJ. Van WijngaerdenE. LazzarinA. RizzardiniG. SprengerH.G. LambertJ. StureG. LeatherD. HughesS. ZucchiP. PearceH. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.Clin. Infect. Dis.201051896397210.1086/65641720828304
     [Google Scholar]
  21. CorreiaI.M. NavarroA.M. Corrêa CordeiroJ.F. GomideE.B.G. MazzonettoL.F. de Sousa OliveiraA. SebastiãoE. AguilarB.A. de AndradeD. MachadoD.R.L. dos SantosA.P. Bone mineral content estimation in people living with HIV: Prediction and validation of sex-specific anthropometric models.Int. J. Environ. Res. Public Health202219191233610.3390/ijerph19191233636231634
     [Google Scholar]
  22. Walker HarrisV. BrownT.T. Bone loss in the HIV-infected patient: Evidence, clinical implications, and treatment strategies.J. Infect. Dis.2012205Suppl 3S391S39810.1093/infdis/jis19922577213
     [Google Scholar]
  23. DaoC.N. PatelP. OvertonE.T. RhameF. PalsS.L. JohnsonC. BushT. BrooksJ.T. Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population.Clin. Infect. Dis.201152339640510.1093/cid/ciq15821217186
     [Google Scholar]
  24. BrownT.T. QaqishR.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review.AIDS200620172165217410.1097/QAD.0b013e32801022eb17086056
     [Google Scholar]
  25. BrownT.T. MoserC. CurrierJ.S. RibaudoH.J. RothenbergJ. KelesidisT. YangO. DubéM.P. MurphyR.L. SteinJ.H. McComseyG.A. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir.J. Infect. Dis.201521281241124910.1093/infdis/jiv19425948863
     [Google Scholar]
  26. KrugerM.J. NellT.A. Bone mineral density in people living with HIV: A narrative review of the literature.AIDS Res. Ther.20171413510.1186/s12981‑017‑0162‑y28747190
     [Google Scholar]
  27. CompstonJ. Osteoporosis and fracture risk associated with HIV infection and treatment.Endocrinol. Metab. Clin. North Am.201443376978010.1016/j.ecl.2014.05.00125169566
     [Google Scholar]
/content/journals/chr/10.2174/011570162X273667231213061301
Loading
Bone Metabolism in Men who Live with HIV Aged 50 years and Over: Impact of Infection Duration
Current HIV Research 22, 65 (2024); https://doi.org/10.2174/011570162X273667231213061301
/content/journals/chr/10.2174/011570162X273667231213061301
/content/journals/chr/10.2174/011570162X273667231213061301
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): antiretroviral treatment; Bone mineral density; HIV; male over 50 years old; osteopenia; osteoporosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test